Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) General Counsel Martin Wilson sold 1,175 shares of Rocket Pharmaceuticals stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $13.05, for a total value of $15,333.75. Following the completion of the sale, the general counsel now directly owns 63,560 shares in the company, valued at $829,458. This represents a 1.82 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Rocket Pharmaceuticals Stock Performance
NASDAQ RCKT opened at $14.10 on Tuesday. The firm has a market capitalization of $1.29 billion, a P/E ratio of -5.13 and a beta of 1.09. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The firm's fifty day moving average price is $17.15 and its two-hundred day moving average price is $19.83. Rocket Pharmaceuticals, Inc. has a 1 year low of $12.62 and a 1 year high of $32.53.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of RCKT. Novo Holdings A S grew its holdings in Rocket Pharmaceuticals by 4.8% during the second quarter. Novo Holdings A S now owns 1,100,000 shares of the biotechnology company's stock worth $23,683,000 after purchasing an additional 50,000 shares during the period. Renaissance Technologies LLC bought a new stake in Rocket Pharmaceuticals in the second quarter valued at approximately $2,144,000. First Turn Management LLC lifted its position in shares of Rocket Pharmaceuticals by 10.8% in the third quarter. First Turn Management LLC now owns 621,306 shares of the biotechnology company's stock valued at $11,476,000 after buying an additional 60,317 shares during the last quarter. Maverick Capital Ltd. boosted its stake in shares of Rocket Pharmaceuticals by 1.0% during the 2nd quarter. Maverick Capital Ltd. now owns 3,928,312 shares of the biotechnology company's stock worth $84,577,000 after acquiring an additional 40,000 shares during the period. Finally, Westfield Capital Management Co. LP increased its holdings in shares of Rocket Pharmaceuticals by 3.8% during the 3rd quarter. Westfield Capital Management Co. LP now owns 4,493,833 shares of the biotechnology company's stock worth $83,001,000 after acquiring an additional 165,911 shares during the last quarter. 98.39% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
One coin could soar when Trump’s elected …
From Weiss Ratings | Ad
Donald Trump wants to be America’s first crypto president.
He was the keynote speaker at the recent Bitcoin conference in Nashville …
Where he told an adoring crowd that the U.S. would become …
“The crypto capital of the planet and the Bitcoin superpower of the world.”
Click here to find out more about what could be Trump and JD Vance’s favorite coin.
A number of research firms recently issued reports on RCKT. Canaccord Genuity Group reissued a "buy" rating and issued a $39.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. Chardan Capital reaffirmed a "buy" rating and set a $62.00 price target on shares of Rocket Pharmaceuticals in a research note on Monday, November 18th. JPMorgan Chase & Co. boosted their price objective on shares of Rocket Pharmaceuticals from $50.00 to $54.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 6th. Scotiabank assumed coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $50.00 target price for the company. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $52.00 price target on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $51.00.
Read Our Latest Report on Rocket Pharmaceuticals
About Rocket Pharmaceuticals
(
Get Free Report)
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
